CRISPR Therapeutics (NASDAQ:CRSP) said Monday that Vertex Pharmaceuticals (VRTX) subsidiary ViaCyte has elected to opt-out of their development partnership for gene-edited stem cell therapies for the ...
CRISPR Therapeutics (NASDAQ:CRSP) executives highlighted progress across its oncology and autoimmune cell therapy pipeline during Citi’s Virtual Oncology Leadership Summit, emphasizing updates on its ...
The company could finally be ready to deliver on years of promise.
Forget Vertex Pharmaceuticals -- CRISPR Therapeutics is a better buy right now.
A version of this Priestley Medal address will be presented at the American Chemical Society Spring 2026 meeting ...
Some three months after the company first disclosed partnership interest, CRISPR Therapeutics board member and SR One CEO Simeon George, M.D., says it’s “still early days” for sealing new deals.
While most of the attention on CRISPR Therapeutics centers on the company’s Vertex-partnered cell therapy and looming FDA advisory committee meeting, Alex Harding, M.D., is cooking up the biotech's ...
ZUG, Switzerland and BOSTON, Feb. 12, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today reported financial results for the fourth quarter and full year ended December 31, 2025.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results